Blue Rabbit Vets Hop for Powerful Drug Import Approval
Published Date: 12/1/2025
Notice
Summary
Blue Rabbit Veterinary LLC wants to become an official importer of two strong veterinary drugs, Etorphine HCI and Thiafentanil, both Schedule II controlled substances. This means vets and animal care pros might get easier access to these important medicines soon. People and companies can share their thoughts or objections online by December 31, 2025, so don’t miss the deadline!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Importer applied to supply zoo/wildlife drugs
On October 28, 2025, Blue Rabbit Veterinary LLC applied to be registered to import Etorphine HCI (code 9059) and Thiafentanil (code 9729), both Schedule II controlled substances. If approved, the company plans to import those drugs in final dosage form for distribution to prospective zoo and wildlife customers.
Registration limited; commercial sale barred
The registration application is limited to the listed import activity and expressly states no other activities for these drug codes are authorized. The authorization will not extend to the import of FDA-approved or non‑approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-21718, Center for Scientific Review; Notice of Closed Meeting
The NIH’s Center for Scientific Review is holding a secret virtual meeting on December 19, 2025, to review important grant applications for research training. This meeting was delayed by a government shutdown but is now urgent to keep funding on track for key health projects. Researchers waiting on NIH money should pay attention because these reviews help decide who gets funded next.
Next: 2025-21720, Bulk Manufacturer of Controlled Substances Application: Benuvia Operations, LLC
Benuvia Operations, LLC wants to become a big-time maker of some powerful drugs like LSD and codeine for research and making new medicine doses. If you have thoughts or concerns, you’ve got until January 30, 2026, to speak up or ask for a hearing. This move could speed up drug research but doesn’t change any sales or money rules right now.